- In 2021, Mydecine made significant progress in creating and commercializing new treatments for mental health and addiction disorders
- It also made a noteworthy shift in focus to reducing expenses and increasing efficiencies for continued clinical trials and the expansion of its IP portfolio
- For 2022, the company plans to build on the progress achieved in 2021
- With new additions to its board, its conditional IRB approval, and the clinical research it has lined up for the new year, Mydecine is confident that it will meet its anticipated capital markets initiatives for 2022
Founded in 2020, Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) has pushed the envelope, particularly in innovating both first- and second-generation novel therapeutics for the treatment of unmet needs in mental health and addiction disorders. Over the past couple of years, it has pursued indications including, but not limited to Post-Traumatic Stress Disorder (“PTSD”), addiction and anxiety, and has made significant progress while at it.
In 2021 the company made significant strides toward creating and commercializing new treatments for mental health and addiction disorders, and received conditional IRB approval to advance its…
NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://ibn.fm/MYCOF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
